Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934
Recruiting
The goal of this study is to learn if GS-1427 is effective in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with GS-1427 with participants treated with placebo. The primary objective of this study is to assess the efficacy of GS-1427, compared with placebo control, in achieving clinical response at Week 12.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/05/2025
Locations: Onyx Clinical Research (Clinic Location), Peoria, Arizona +184 locations
Conditions: Ulcerative Colitis
Register for Updates
Group Activities to Support Addiction Recovery
NCT07071883
Recruiting
The purpose of this study is to pilot the use of Holotropic Breathwork (HB) for individuals seeking to recover from addiction. The study will have two arms: A--for individuals in residential treatment programs, B--for individuals living in the community. Arm A will use a cluster randomized intervention, providing HB for individuals at two facilities and a Multiple Modality (MM) intervention (yoga, meditation, and a film/discussion) at a third facility. In Arm B, we seek to measure the feasibilit... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
08/05/2025
Locations: University of Nebraska Medical Center, Lincoln, Nebraska
Conditions: Addiction, Substance Use Disorders (SUD)
Register for Updates
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
NCT06585488
Recruiting
This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as monotherapy in participants with advanced or metastatic solid tumors harboring KRAS mutations or amplification, as well as when used in combination with tislelizumab (also known as BGB-A317) in participants with nonsquamous non-small cell lung cancer (NSCLC) and used in c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California +19 locations
Conditions: Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Cancer, Advanced Esophageal Adenocarcinoma
Register for Updates
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
NCT06344130
Recruiting
Background: Glioblastoma (GBM) is a cancer of the brain. Current survival rates for people with GBM are poor; survival ranges from 5.2 months to 39 months. Most tumors come back within months or years after treatment, and when they do, they are worse: Overall survival drops to less than 10 months. No standard treatment exists for people whose GBM has returned after radiation therapy. Objective: To find a safe schedule for using radiation to treat GBM tumors that returned after initial radiati... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/05/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Astrocytoma, Glioma, Recurrent Glioblastoma
Register for Updates
TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma
NCT07118202
Recruiting
The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced hepatocellular carcinoma (HCC) who have no standard of care options can affect patients survival. The main questions it aims to answer are: * will the TheraBionic P1 device affect overall survival in advance HCC * the long term safety and tolerability of the TheraBionic P1 device * assessment of how the disease responded to the TheraBionic P1 device
Gender:
ALL
Ages:
22 years and above
Trial Updated:
08/05/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Hepatocellular Carcinoma Recurrent
Register for Updates
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
NCT06512883
Recruiting
The main purpose of study is to assess the safety, tolerability, and pharmacokinetic (PK) of benralizumab.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/05/2025
Locations: Research Site, Aurora, Colorado +5 locations
Conditions: Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Register for Updates
Changes in Hydration Status of PepsiCo Frontline Workers in a Manufacturing Facility Over the Course of Multiple Shifts
NCT07117773
Recruiting
Physically demanding occupations (PDO) require high levels of energy expenditure, mental acuity, and technical skills. Sometimes this work is performed in extreme environments during hot/humid summer months. Previous research shows that dehydration and heat stress can increase risk of heat-related illness, reduced cognitive function, and work capacity. While this impact of physically demanding work in extreme environmental conditions is often studied in firefighters, military personnel, and athl... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/05/2025
Locations: Gatorade Sports Science Institute, Bradenton, Florida
Conditions: Hydration Status
Register for Updates
Oxytocin/Foley vs. Oxytocin for Induction in Patients With PPROM
NCT07119398
Recruiting
Data on the optimal mode of labor induction after preterm prelabor rupture of membranes (PPROM) is lacking. Studies have shown no difference between oxytocin and misoprostol use for labor induction in this cohort (1). The preponderance of evidence from term pregnancies suggests that Foley catheter coupled with oxytocin is better than oxytocin alone, with a higher rate of delivery within 24 hours when a Foley catheter followed by oxytocin is compared to oxytocin alone. However, the use of a Foley... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
08/05/2025
Locations: Sentara Norfolk General Hospital, Norfolk, Virginia
Conditions: Preterm PROM (Pregnancy)
Register for Updates
Telehealth to Improve Quality of Life in Persons Living in Rural Texas
NCT07119710
Recruiting
The overarching goal of this project is to evaluate a current evidence-based practice, Cognitive Behavioral Therapy, for mental health conditions against Cognitive Behavioral Therapy plus two check-in calls a week for adults living in rural Texas.
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
08/05/2025
Locations: Garrison Institute on Aging, Lubbock, Texas
Conditions: Mental Health Issue, Quality of Life
Register for Updates
Laying the Foundation for Building a Resilient KPNC Community in the Face of Worsening Air Quality Due to Wildfire Smoke
NCT07118189
Recruiting
The overarching goal of this project is to conduct a pilot intervention in high-risk Kaiser Permanente Northern California patients with chronic obstructive pulmonary disease to mitigate their exposure to poor air quality and decrease exacerbations of lung disease.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
08/05/2025
Locations: Kaiser Permanente Northern California Division of Research, Pleasanton, California
Conditions: Chronic Obstructive Pulmonary Disease (COPD), Exacerbation of COPD, Exacerbation of Chronic Obstructive Pulmonary Disease
Register for Updates
A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP
NCT07119125
Recruiting
The principal aim of this study is to obtain safety and tolerability data when MRT-8102 is administered orally as single and multiple doses to healthy participants and participants at cardiovascular risk with elevated CRP. This information, together with the pharmacokinetic (PK) data, will help establish the dose and dosing regimen suitable for future studies. The study drug, MRT-8102, is experimental. This is the first study in which MRT-8102 will be given to humans. Part 1: Healthy participa... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/05/2025
Locations: ICON Clinical Research, Lenexa, Kansas
Conditions: Healthy Volunteers, Elevated CRP
Register for Updates
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
NCT07117487
Recruiting
The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/05/2025
Locations: Velocity Clinical Research, Denver, Denver, Colorado +10 locations
Conditions: Respiratory Syncytial Virus
Register for Updates